A phase I dose-escalation study of aflibercept administered in combination with pemetrexed and cisplatin in patients with advanced solid tumours

BACKGROUND: To evaluate the safety, pharmacokinetics (PKs), and pharmacodynamics of aflibercept, and to identify the recommended phase II dose (RP2D) of aflibercept in combination with pemetrexed and cisplatin. METHODS: Aflibercept was administered at escalating doses of 2, 4, or 6 mg kg(−1) in comb...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Diaz-Padilla, I, Siu, L L, San Pedro-Salcedo, M, Razak, A R A, Colevas, A D, Shepherd, F A, Leighl, N B, Neal, J W, Thibault, A, Liu, L, Lisano, J, Gao, B, Lawson, E B, Wakelee, H A
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Nature Publishing Group 2012
Konular:
Clinical Study
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3419963/
https://ncbi.nlm.nih.gov/pubmed/22805331
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2012.319
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller